Virtus LifeSci Biotech Products ETF (BBP)

NYSEARCA: BBP · Real-Time Price · USD
61.94
+0.54 (0.87%)
Nov 20, 2024, 12:14 PM EST - Market closed
0.87%
Assets $21.20M
Expense Ratio 0.79%
PE Ratio n/a
Shares Out 350,004
Dividend (ttm) n/a
Dividend Yield n/a
Ex-Dividend Date n/a
Payout Ratio n/a
1-Year Return +25.84%
Volume 1,234
Open 61.40
Previous Close 61.40
Day's Range 61.40 - 61.94
52-Week Low 48.98
52-Week High 69.12
Beta 0.62
Holdings 65
Inception Date Dec 17, 2014

About BBP

Fund Home Page

The Virtus LifeSci Biotech Products ETF (BBP) is an exchange-traded fund that is based on the LifeSci Biotechnology Products index. The fund tracks an index of US-listed biotechnology companies considered to be in the product stage by the index provider. BBP was launched on Dec 17, 2014 and is issued by Virtus Investment Partners.

Asset Class Equity
Category Health
Region North America
Stock Exchange NYSEARCA
Ticker Symbol BBP
Index Tracked LifeSci Biotechnology Products Index

Top 10 Holdings

25.10% of assets
Name Symbol Weight
Travere Therapeutics, Inc. TVTX 3.67%
ADMA Biologics, Inc. ADMA 2.92%
TG Therapeutics, Inc. TGTX 2.77%
Mirum Pharmaceuticals, Inc. MIRM 2.41%
Exelixis, Inc. EXEL 2.39%
Aurinia Pharmaceuticals Inc. AUPH 2.32%
Alnylam Pharmaceuticals, Inc. ALNY 2.24%
Tarsus Pharmaceuticals, Inc. TARS 2.16%
Gilead Sciences, Inc. GILD 2.11%
Ligand Pharmaceuticals Incorporated LGND 2.10%
View More Holdings

News

Can Health Care Stocks Outperform Again In 2023?

How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.

2 years ago - Seeking Alpha

Biotechs Ready To Roar

Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotec...

3 years ago - Seeking Alpha

Biotech Innovations Remain At Forefront

The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively r...

3 years ago - Seeking Alpha

Moving Beyond COVID In Biopharma

Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12,...

3 years ago - Seeking Alpha

Late-stage biotech ETFs rally Monday on virus treatment hopes

Late-stage biotech exchange-traded funds were among the day's biggest gainers Monday as investors pinned their hopes on medical responses to the novel coronavirus. The ALPS Medical Breakthroughs ETF ...

Other symbols: SBIO
4 years ago - Market Watch